Results 221 to 230 of about 92,043 (285)

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 5, Page 1218-1225, May 2026.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young, Jennifer E. Murphy, Mallory Chavannes, Jennifer L. Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses, Sandra C. Kim   +10 more
wiley   +1 more source

Prevalence of disorders of gut–brain‐interaction in pediatric patients with in‐remission inflammatory bowel disease: An Italian multicenter study

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 5, Page 1171-1177, May 2026.
Abstract Objectives Pediatric patients with in‐remission inflammatory bowel disease (IBD) often report persistent gastrointestinal symptoms, suggesting a potential overlap with disorders of gut–brain‐interaction (DGBIs). While DGBIs affect up to 40% of the general population, their prevalence in quiescent IBD children remains limited.
Giovanna Quatrale, Niccolo’ Chirico, Luigi Colecchia, Giuseppe Stella, Francesco Proli, Pietro Pisano, Erminia Romeo, Paola De Angelis, Licia Pensabene, Giovanni Marasco, Giovanni Di Nardo, Giovanni Barbara, Antonio Gasbarrini, Franco Scaldaferri, Valentina Giorgio   +14 more
wiley   +1 more source

Amygdalin synergizes with the TNF-α monoclonal antibody infliximab to modulate HSP90 and related necro-inflammatory/oxidative stress pathways in a rat model of hepatic I/R. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Mohamed RA, Ghoneim ME, Tawfiq RA, El Sayed NF.   +3 more
europepmc   +1 more source

Significant kidney impairment in pediatric inflammatory bowel disease and practice points for pediatric gastroenterologists

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 5, Page 1251-1260, May 2026.
Abstract Objectives Children with inflammatory bowel disease (IBD) have an increased risk of developing kidney disorders, which may cause significant kidney function impairment (SKI) or lead to chronic kidney disease (CKD). In this study we aimed to provide insights in causes and diagnoses of SKI cases and to provide recommendations for pediatric ...
Stephanie A. Vuijk, Renz C. W. Klomberg, Tobias Schwerd, Anne M. Griffiths, Séamus Hussey, Matthew W. Carroll, Petter Malmborg, Protima Deb, Margreet Wessels, Natalia Mouratidou, Stephanie van Biervliet, Michael Friedt, Susie Minson, Femke H. M. Vrieling‐Prince, Nicholas M. Croft, Lissy de Ridder, the PIBD‐SETQuality Safety Registry Collaborative Group   +16 more
wiley   +1 more source

Steroid-Refractory Warm Autoimmune Haemolytic Anaemia Complicating Ulcerative Colitis in Pregnancy: A Case Report and Management Considerations. [PDF]

Cureus
William J, Lahiff C, Couto M.
europepmc   +1 more source

Observational study of metastatic vulvar Crohn's disease in the pediatric population

JPGN Reports, Volume 7, Issue 2, Page 207-212, May 2026.
Abstract Objective Metastatic vulvar Crohn's disease (MVCD) is a rare cutaneous manifestation of Crohn's disease (CD), especially in pediatric patients. The objective of this study is to assess presentation, diagnosis, and treatment for pediatric MVCD in the largest cohort reported. Methods This is a retrospective review of pediatric patients with MVCD
Deborah Winograd, Afua Addo, Taryn Wassmer, Jennifer Hellmann, Daniel Mallon, Kalyani Marathe, Christine Pennesi   +6 more
wiley   +1 more source

RETRACTED: Cordaro et al. Role of Etanercept and Infliximab on Nociceptive Changes Induced by the Experimental Model of Fibromyalgia. <i>Int. J. Mol. Sci.</i> 2022, <i>23</i>, 6139. [PDF]

Int J Mol Sci
Cordaro M, Siracusa R, D'Amico R, Genovese T, Franco G, Marino Y, Paola DD, Cuzzocrea S, Impellizzeri D, Paola RD, Fusco R.   +10 more
europepmc   +1 more source

Responsible laboratory surveillance of pediatric patients with inflammatory bowel disease on biologic infusion therapy

JPGN Reports, Volume 7, Issue 2, Page 301-305, May 2026.
Abstract The annual healthcare spending on pediatric inflammatory bowel disease (IBD) has increased over time. The objectives of the study were to investigate the cost of routine laboratory surveillance in pediatric IBD patients during outpatient maintenance biologic infusions and determine their impact on clinical management.
Tanmai Shah, Ashwin Agrawal, Héctor E. Alcalá, Anupama Chawla   +3 more
wiley   +1 more source

Successful upadacitinib treatment in anti-TNF-refractory intestinal Behçet's disease: a case report and literature review. [PDF]

Front Med (Lausanne)
Shi Y, Zhang M, Wang X, Liu F, Chen J, Guo W.   +5 more
europepmc   +1 more source

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease

JPGN Reports, Volume 7, Issue 2, Page 296-300, May 2026.
Abstract Objectives Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD).
Evan Greenhall, Nina Gautam, Paula Prieto‐Jimenez, Elizabeth Hilow, Ashish Patel, Brad Pasternak   +5 more
wiley   +1 more source